COMMUNIQUÉS West-GlobeNewswire
-
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
22/06/2026 -
Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
22/06/2026 -
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
22/06/2026 -
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
22/06/2026 -
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
22/06/2026 -
NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
22/06/2026 -
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
22/06/2026 -
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
22/06/2026 -
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
22/06/2026 -
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
22/06/2026 -
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
22/06/2026 -
SeaStar Medical to Present at Upcoming Investor Summit Conference
22/06/2026 -
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
22/06/2026 -
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
22/06/2026 -
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
22/06/2026 -
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
22/06/2026 -
Novo Nordisk A/S - share repurchase programme
22/06/2026 -
Parexel Launches Parexel Biotech Incubator to Connect Early-Stage Innovation with Clinical Development Expertise
22/06/2026 -
INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
22/06/2026
Pages